MAGNEVIST

This brand name is authorized in United States. It is also authorized in Austria, Canada, Cyprus, Estonia, Lithuania, Poland, Singapore, South Africa, UK.

Active ingredients

The drug MAGNEVIST contains one active pharmaceutical ingredient (API):

1	Gadopentetate dimeglumine UNII K2I13DR72L - GADOPENTETIC ACID
	Gadopentetic acid is a paramagnetic contrast agent for magnetic resonance imaging.
	Read more about Gadopentetate dimeglumine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MAGNEVIST Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V08CA01	Gadopentetic acid	V Various → V08 Contrast media → V08C Magnetic resonance imaging contrast media → V08CA Paramagnetic contrast media
Discover more medicines within V08CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	01989987
EE	Ravimiamet	1018392, 1079467, 1079478, 1079489, 1079490, 1079502, 1084003, 1084014, 1624249
GB	Medicines & Healthcare Products Regulatory Agency	90571
LT	Valstybinė vaistų kontrolės tarnyba	1007951, 1010499, 1010500, 1010501, 1031767
PL	Rejestru Produktów Leczniczych	100195615
SG	Health Sciences Authority	04323P
US	FDA, National Drug Code	50419-188
ZA	Health Products Regulatory Authority	28/28/0639, 28/28/0640, 28/28/0641, 36/28/0026, 36/28/0027, W/28/199